organization · Reporting owner
JEB Partners, L.P.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAIN SCIENTIFIC INC.BRSF · Entity 124256 | 10% owner | June 15, 2022 | August 04, 2022 |
| Modular Medical, Inc.MODD · Entity 7488 | Director by Deputization | April 24, 2025 | April 28, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAIN SCIENTIFIC INC.
Report date June 15, 2022 · Filed August 04, 2022
Jointly reported with MANCHESTER MANAGEMENT CO LLC, MANCHESTER MANAGEMENT PR, LLC, Manchester Explorer, L.P., BESSER JAMES E, FRANK MORGAN C.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 19,545,187 |
Reported balance
Holding disclosure · report date 2022-06-15 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 19,545,187 F1: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 12,816,831 |
Reported balance
Holding disclosure · report date 2022-06-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,816,831 F2: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 8,028,706 |
Reported balance
Holding disclosure · report date 2022-06-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 8,028,706 F3: The reported securities and warrants are directly owned by James E. Besser in his personal capacity. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.25 | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2022-06-15 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: The reported warrants are exercisable as of the issue date, subject to certain conditions. F5: The reported warrants expire at 5:00pm E.D.T. on the fourth anniversary of the issue date, subject to certain conditions. F1: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.25 | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2022-06-15 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F4: The reported warrants are exercisable as of the issue date, subject to certain conditions. F5: The reported warrants expire at 5:00pm E.D.T. on the fourth anniversary of the issue date, subject to certain conditions. F2: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.25 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-06-15 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F4: The reported warrants are exercisable as of the issue date, subject to certain conditions. F5: The reported warrants expire at 5:00pm E.D.T. on the fourth anniversary of the issue date, subject to certain conditions. F3: The reported securities and warrants are directly owned by James E. Besser in his personal capacity. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2031-10-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-06-15 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed F6: The reported warrants are subject to a blocker provision that prevents James E. Besser from exercising the warrants if he would be more than a 4.99% beneficial owner of the Common Stock, $0.001 par value, following such exercise. The foregoing description of the warrant does not purport to be complete and is subject to and qualified in its entirety by reference to the Common Stock Purchase Warrant included as Exhibit 4.1 of the Issuer's 8-K filed on October 7, 2021, which is incorporated by reference. F3: The reported securities and warrants are directly owned by James E. Besser in his personal capacity. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities and warrants are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company, LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR, and (iv) Morgan Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2: The reported securities and warrants are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3: The reported securities and warrants are directly owned by James E. Besser in his personal capacity.
F4: The reported warrants are exercisable as of the issue date, subject to certain conditions.
F5: The reported warrants expire at 5:00pm E.D.T. on the fourth anniversary of the issue date, subject to certain conditions.
F6: The reported warrants are subject to a blocker provision that prevents James E. Besser from exercising the warrants if he would be more than a 4.99% beneficial owner of the Common Stock, $0.001 par value, following such exercise. The foregoing description of the warrant does not purport to be complete and is subject to and qualified in its entirety by reference to the Common Stock Purchase Warrant included as Exhibit 4.1 of the Issuer's 8-K filed on October 7, 2021, which is incorporated by reference.
Modular Medical, Inc.
Report date April 24, 2025 · Filed April 28, 2025
Jointly reported with MANCHESTER MANAGEMENT CO LLC, MANCHESTER MANAGEMENT PR, LLC, BESSER JAMES E, FRANK MORGAN C., Manchester Explorer, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.94 · Expires 2035-04-24 | Direct | 125,000 |
Reported balance
After 2025-04-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-24 · Grant · Acquired 125,000 · Balance 125,000 F1: The options were granted to the Reporting Person in accordance with the Issuer's Fiscal 2026 Two-Part FDA Submission and Product Milestone Bonus Program. The options will vest in two parts: (i) 50% if the Issuer submits a 510k related to MODDi to the FDA on or before October 31, 2025 and (ii) the remaining 50% if the manufacturing line is validated on MODDi with capacity to serve 6,000 patients by March 15, 2026. F2: The reported securities are directly owned by James E. Besser in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2035-03-31 | Direct | 1,875 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 1,875 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2035-03-31 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 9,375 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2034-12-31 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 9,375 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.56 · Expires 2034-06-30 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 9,375 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.95 · Expires 2034-03-31 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 9,375 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.78 · Expires 2033-12-29 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 9,375 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.11 · Expires 2033-10-02 | Direct | 135,136 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 135,136 F8: This option has vested since (i) all verification and validation testing for the Registrant's initial pump product was completed by December 31, 2023 and (ii) the 510(K) premarket submission to the U.S. Food and Drug Administration ("FDA") for the Registrant's initial pump product was completed by January 31, 2024. F2: The reported securities are directly owned by James E. Besser in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2033-09-30 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 9,375 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2033-06-30 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 9,375 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.44 · Expires 2033-03-31 | Direct | 9,375 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 9,375 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2032-12-31 | Direct | 1,875 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 1,875 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2032-12-31 | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 7,500 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $4.34 · Expires 2032-09-30 | Direct | 1,875 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 1,875 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $4.34 · Expires 2032-09-30 | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 7,500 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $5.16 · Expires 2032-06-30 | Direct | 3,634 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 3,634 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $5.16 · Expires 2032-07-19 | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · Balance 7,500 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2032-03-31 | Direct | 4,486 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · Balance 4,486 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2032-03-31 | Direct | 17,943 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · Balance 17,943 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2031-12-31 | Direct | 9,987 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · Balance 9,987 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2031-12-31 | Direct | 2,497 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · Balance 2,497 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $2.98 · Expires 2031-09-30 | Direct | 8,389 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · Balance 8,389 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F9: These Shares reflect a 3 for 1 reverse stock split effective November 26, 2021. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $2.98 · Expires 2031-09-30 | Direct | 2,097 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 28
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 28 · Balance 2,097 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F9: These Shares reflect a 3 for 1 reverse stock split effective November 26, 2021. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $5.90 · Expires 2031-06-30 | Direct | 5,297 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 29
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 29 · Balance 5,297 F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date. F9: These Shares reflect a 3 for 1 reverse stock split effective November 26, 2021. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $2.87 · Expires 2030-05-12 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 30
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 30 · Balance 50,000 F9: These Shares reflect a 3 for 1 reverse stock split effective November 26, 2021. F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2029-03-25 | IndirectSee footnote | 260,416 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 260,416 F5: Manchester Explorer, L.P. ("Explorer") acquired 260,416 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025. F6: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR and (iv) Morgan C. Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $6.60 · Expires 2027-02-14 | IndirectSee footnote | 234,274 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · Balance 234,274 F6: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR and (iv) Morgan C. Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $6.60 · Expires 2027-02-10 | IndirectSee footnote | 300,000 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · Balance 300,000 F6: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR and (iv) Morgan C. Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $8.61 · Expires 2027-02-06 | IndirectSee footnote | 119,237 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · Balance 119,237 F6: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR and (iv) Morgan C. Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2029-03-25 | Direct | 78,125 |
Reported balance
Holding disclosure · report date 2025-04-24 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 78,125 F7: James E. Besser acquired 78,125 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025. F2: The reported securities are directly owned by James E. Besser in his personal capacity. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted to the Reporting Person in accordance with the Issuer's Fiscal 2026 Two-Part FDA Submission and Product Milestone Bonus Program. The options will vest in two parts: (i) 50% if the Issuer submits a 510k related to MODDi to the FDA on or before October 31, 2025 and (ii) the remaining 50% if the manufacturing line is validated on MODDi with capacity to serve 6,000 patients by March 15, 2026.
F2: The reported securities are directly owned by James E. Besser in his personal capacity.
F3: The options were granted to the Reporting Person in accordance with the Issuer's Outside Director Compensation Plan, and the options were fully vested and exercisable on the grant date.
F4: The reported securities are directly owned by Morgan C. Frank in his personal capacity.
F5: Manchester Explorer, L.P. ("Explorer") acquired 260,416 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025.
F6: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) James E. Besser, the managing member of Manchester Management and Manchester PR and (iv) Morgan C. Frank, who serves as a portfolio manager and as a consultant for Explorer. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F7: James E. Besser acquired 78,125 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025.
F8: This option has vested since (i) all verification and validation testing for the Registrant's initial pump product was completed by December 31, 2023 and (ii) the 510(K) premarket submission to the U.S. Food and Drug Administration ("FDA") for the Registrant's initial pump product was completed by January 31, 2024.
F9: These Shares reflect a 3 for 1 reverse stock split effective November 26, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 24, 2025 Filed Apr 28, 2025 16:39 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantOption to purchase common stock · Derivative | 125,000 | $0.94 Strike: $0.94 | $117,500.00 |
DisclosureSEC source: 0000919574-25-002637 · ownership.xml · derivative · entry 1 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director · Chief Executive Officer · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner FRANK MORGAN C. · CIK 0001593072 · Director Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock, par value $0.001 per share · 125,000 shares Expires 2035-04-24 F1 · security: The options were granted to the Reporting Person in accordance with the Issuer's Fiscal 2026 Two-Part FDA Submission and Product Milestone Bonus Program. The options will vest in two parts: (i) 50% if the Issuer submits a 510k related to MODDi to the FDA on or before October 31, 2025 and (ii) the remaining 50% if the manufacturing line is validated on MODDi with capacity to serve 6,000 patients by March 15, 2026. F1 · price: The options were granted to the Reporting Person in accordance with the Issuer's Fiscal 2026 Two-Part FDA Submission and Product Milestone Bonus Program. The options will vest in two parts: (i) 50% if the Issuer submits a 510k related to MODDi to the FDA on or before October 31, 2025 and (ii) the remaining 50% if the manufacturing line is validated on MODDi with capacity to serve 6,000 patients by March 15, 2026. F2 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:34 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantCommon Stock Purchase Warrant · Derivative | 78,125 | $1.12 Strike: $1.12 | $87,500.00 |
DisclosureSEC source: 0000919574-25-002089 · ownership.xml · derivative · entry 6 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director · Chief Executive Officer · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner FRANK MORGAN C. · CIK 0001593072 · Director Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,125 Underlying: Common Stock, par value $0.001 per share · 78,125 shares Expires 2029-03-25 F3 · price: James E. Besser acquired 78,125 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025. F3 · derivative.exercise_date: James E. Besser acquired 78,125 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025. F4 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:34 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantCommon Stock Purchase Warrant · Derivative | 260,416 | $1.12 Strike: $1.12 | $291,665.92 |
DisclosureSEC source: 0000919574-25-002089 · ownership.xml · derivative · entry 5 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director · Chief Executive Officer · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner FRANK MORGAN C. · CIK 0001593072 · Director Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 260,416 Underlying: Common Stock, par value $0.001 per share · 260,416 shares Expires 2029-03-25 F1 · price: Manchester Explorer, L.P. ("Explorer") acquired 260,416 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025. F1 · derivative.exercise_date: Manchester Explorer, L.P. ("Explorer") acquired 260,416 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025. F2 · ownership.nature: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) and James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:34 UTC | Modular Medical, Inc. MODD · Entity 7488 | PurchaseCommon Stock, par value $0.001 per share | 156,250 | $1.92 | $300,000.00 |
DisclosureSEC source: 0000919574-25-002089 · ownership.xml · nonDerivative · entry 2 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director · Chief Executive Officer · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner FRANK MORGAN C. · CIK 0001593072 · Director Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 422,000 F3 · price: James E. Besser acquired 78,125 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025. F4 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:34 UTC | Modular Medical, Inc. MODD · Entity 7488 | PurchaseCommon Stock, par value $0.001 per share | 520,832 | $1.92 | $999,997.44 |
DisclosureSEC source: 0000919574-25-002089 · ownership.xml · nonDerivative · entry 1 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director · Chief Executive Officer · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner FRANK MORGAN C. · CIK 0001593072 · Director Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,805,575 F1 · price: Manchester Explorer, L.P. ("Explorer") acquired 260,416 units consisting of two shares of Common Stock, par value $0.001 per share and one warrant to purchase one share of Common Stock, par value $0.001 per share. It is anticipated that the warrants will become exercisable on or about March 25, 2025. F2 · ownership.nature: The reported securities are owned directly by Explorer and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) and James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 18:05 UTC | Modular Medical, Inc. MODD · Entity 7488 | PurchaseCommon Stock, par value $0.001 per share | 21,000 | $1.68 | $35,235.90 |
DisclosureSEC source: 0000919574-24-007009 · ownership.xml · nonDerivative · entry 1 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner Manchester Explorer, L.P. · CIK 0001411524 · 10% owner · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,750 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.65 to $1.73. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity. Read SEC document |
| November 27, 2024 Filed Nov 29, 2024 10:00 UTC | Modular Medical, Inc. MODD · Entity 7488 | PurchaseCommon Stock, par value $0.001 per share | 100,000 | $1.69 | $168,950.00 |
DisclosureSEC source: 0000919574-24-006936 · ownership.xml · nonDerivative · entry 1 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner Manchester Explorer, L.P. · CIK 0001411524 · 10% owner · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization FRANK MORGAN C. · CIK 0001593072 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,750 F1 · price: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) and James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F2 · ownership.direct: The reported securities are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management, the general partner of JEB Partners, (ii) Manchester PR, the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 19:46 UTC | Modular Medical, Inc. MODD · Entity 7488 | PurchaseCommon Stock, par value $0.001 per share | 166,666 | $1.50 | $249,999.00 |
DisclosureSEC source: 0000919574-24-006890 · ownership.xml · nonDerivative · entry 1 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Chief Executive Officer · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,284,743 F1 · ownership.nature: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) and James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 16:50 UTC | Modular Medical, Inc. MODD · Entity 7488 | PurchaseCommon Stock, par value $0.001 per share | 900,000 | $1.10 | $990,000.00 |
DisclosureSEC source: 0000919574-24-001612 · ownership.xml · nonDerivative · entry 1 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · Director · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · Director · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner Manchester Explorer, L.P. · CIK 0001411524 · Director by Deputization JEB Partners, L.P. · CIK 0001093241 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,118,227 F1 · ownership.direct: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) and James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: The reported securities are owned directly by Manchester Explorer, L.P. ("Explorer") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of Explorer, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, (iii) and James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 10:29 UTC | Modular Medical, Inc. MODD · Entity 7488 | PurchaseCommon Stock, par value $0.001 per share | 20,000 | $1.10 | $21,974.00 |
DisclosureSEC source: 0000919574-23-005719 · ownership.xml · nonDerivative · entry 2 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner JEB Partners, L.P. · CIK 0001093241 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,750 F2 · ownership.direct: The reported securities are directly owned by James E. Besser in his personal capacity. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 10:29 UTC | Modular Medical, Inc. MODD · Entity 7488 | PurchaseCommon Stock, par value $0.001 per share | 13,000 | $1.04 | $13,548.60 |
DisclosureSEC source: 0000919574-23-005719 · ownership.xml · nonDerivative · entry 1 MANCHESTER MANAGEMENT CO LLC · CIK 0001169253 · 10% owner · Director by Deputization MANCHESTER MANAGEMENT PR, LLC · CIK 0001735534 · 10% owner · Director by Deputization BESSER JAMES E · CIK 0001512127 · Chief Executive Officer · 10% owner JEB Partners, L.P. · CIK 0001093241 · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 330,473 F1 · ownership.nature: The reported securities are owned directly by JEB Partners, L.P. ("JEB Partners") and may be deemed to be indirectly beneficially owned by (i) Manchester Management Company LLC ("Manchester Management"), the general partner of JEB Partners, (ii) Manchester Management PR, LLC ("Manchester PR"), the investment adviser to Manchester Management, and (iii) James E. Besser, the managing member of Manchester Management and Manchester PR. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.